Relapse rates tend to be highest within that first year after treatment
Baek, HM15211, a novel GLP-1/GIP/glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: a phase 1b/2a, multi-center, randomized, placebo-controlled trial, J
Lifestyle & Weight Management Consumers: Communicate appetite support and digestive balance, emphasizing daily wellness
Across the platforms theyve built, where onboarding, telehealth, prescriptions and coaching all sit inside a single patient portal, early drop-off runs at around 35% over the first three months
How I track effectiveness without obsessing Im big on soft tracking because I dont want wellness to become a full-time job